Dexa Medica Group

Quick facts

Marketed products

• placebo tablet of DLBS1033
  A placebo tablet containing no active pharmaceutical ingredient, used as a control comparator in clinical trials.

Phase 3 pipeline

• DLBS3233 · Hepatology / Gastroenterology
  DLBS3233 is a bioactive fraction derived from Cinnamomum burmannii that modulates lipid metabolism and reduces hepatic steatosis through multiple pathways.
• Placebo caplet of Metformin XR · Diabetes
  This is a placebo formulation with no active pharmacological mechanism.
• Placebo capsule of DLBS3233
  This is a placebo capsule used as a control in clinical trials of DLBS3233.
• Placebo of Reconyl
  This drug is a placebo, meaning it has no active therapeutic effect.
• Reconyl · Other

Phase 2 pipeline

• DLBS-32
• DLBS1442 100
• DLBS1442 200
• Predimenol tablet
• Proliverenol · Gastroenterology
• Silfamin · Other

Phase 1 pipeline

• Pramipexole Boehringer Ingelheim Pharma
• Pramipexole Dexa Medica

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Dexa Medica Group portfolio CI brief
• Dexa Medica Group pipeline updates RSS